Qiagen has initiated a third-party partnering program to expand its clinical digital PCR platform's test menu, signing South Korea-based Gencurix Oncology as the inaugural partner. The collaboration focuses on developing multiplexed dPCR oncology assays for tissue and liquid biopsies, combining Gencurix’s assay expertise with Qiagen’s commercialization and global reach. Qiagen’s automated QiAcuityDx system supports high-throughput sample processing with integrated thermal cycling and imaging controls. This initiative aims to deliver precision molecular diagnostics complementary to existing technologies like qPCR and next-generation sequencing, enhancing cancer detection and treatment monitoring.